Innate Pharma (IPHA) Non-Current Assets (2017 - 2025)

Innate Pharma (IPHA) has disclosed Non-Current Assets for 8 consecutive years, with $27.1 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Non-Current Assets fell 7.47% year-over-year to $27.1 million, compared with a TTM value of $27.1 million through Dec 2024, down 7.47%, and an annual FY2024 reading of $27.4 million, down 6.78% over the prior year.
  • Non-Current Assets was $27.1 million for Q4 2024 at Innate Pharma, down from $29.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $159.7 million in Q4 2020 and bottomed at $27.1 million in Q4 2024.
  • Average Non-Current Assets over 5 years is $84.9 million, with a median of $60.7 million recorded in 2022.
  • The sharpest move saw Non-Current Assets decreased 7.44% in 2021, then crashed 58.97% in 2022.
  • Year by year, Non-Current Assets stood at $159.7 million in 2020, then decreased by 7.44% to $147.8 million in 2021, then tumbled by 58.97% to $60.7 million in 2022, then plummeted by 51.81% to $29.2 million in 2023, then decreased by 7.47% to $27.1 million in 2024.
  • Business Quant data shows Non-Current Assets for IPHA at $27.1 million in Q4 2024, $29.2 million in Q4 2023, and $60.7 million in Q4 2022.